Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

20.45USD
19 Sep 2018
Change (% chg)

$0.95 (+4.87%)
Prev Close
$19.50
Open
$19.80
Day's High
$20.50
Day's Low
$19.60
Volume
6,801
Avg. Vol
18,048
52-wk High
$23.00
52-wk Low
$9.25

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine Group Reports Qtrly Loss Per Share $0.53
Wednesday, 8 Aug 2018 07:30am EDT 

Aug 8 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS SECOND QUARTER AND FIRST HALF 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.QTRLY LOSS PER SHARE $0.53.QTRLY REVENUE $77,313 VERSUS $62,914.CASH AND CASH EQUIVALENTS AT END OF PERIOD $24.8 MILLION COMPARED WITH $21.6 MILLION ON DEC 31, 2017.  Full Article

Cellular Biomedicine Announces Positive Clinical Data Of Knee Osteoarthritis China Phase I Trial
Friday, 16 Mar 2018 07:00am EDT 

March 16 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ANNOUNCES POSITIVE 48-WEEK CLINICAL DATA OF ALLOJOIN™ HUMAN ADIPOSE-DERIVED MESENCHYMAL PROGENITOR CELL (HAMPC) KNEE OSTEOARTHRITIS (KOA) CHINA PHASE I TRIAL.CELLULAR BIOMEDICINE GROUP - STUDY SHOWED ALLOJOIN TO HAVE GOOD SAFETY TOLERANCE AND EARLY SIGNS OF EFFICACY IN PREVENTING CARTILAGE DETERIORATION.CELLULAR BIOMEDICINE - PRIMARY END POINT SHOWED A SIGNIFICANT IMPROVEMENT AT 12 WEEKS POST ALLOJOIN CELL THERAPY, CONTINUED IMPROVEMENT AT 48 WEEKS.CELLULAR BIOMEDICINE - SECONDARY END POINT SHOWED INCREASED TENDENCY VERSUS THAT AT BASELINE 0 WEEKS, VERSUS NORMAL CARTILAGE DETERIORATION AS RESULT OF AGING.CELLULAR BIOMEDICINE - DE-PRIORITIZING U.S. ALLOJOIN OPERATION & CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE PROJECT TERMINATED, EFFECTIVE MARCH 14.CELLULAR BIOMEDICINE - COMMON SIDE EFFECTS WERE TEMPORARY LOCAL REACTIONS INCLUDING SORENESS, SWELLING AT INJECTION SITE IN STUDY.CELLULAR BIOMEDICINE GROUP INC - TO DATE, NO SERIOUS ADVERSE EVENTS RELATED TO ALLOJOIN THERAPY HAVE BEEN REPORTED.CELLULAR BIOMEDICINE- 2 PATIENTS WHO UNDERWENT ONE DOSE OF INJECTIONS DROPPED OUT OF STUDY AS THEIR KNEE JOINTS WERE MORE PAINFUL AFTER INJECTION.  Full Article

Cellular Biomedicine Group Reports Full-Year 2017 Financial Results And Recent Operational Progress
Tuesday, 6 Mar 2018 09:27am EST 

March 6 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP REPORTS FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.CELLULAR BIOMEDICINE GROUP INC - HAD WORKING CAPITAL OF $20.9 MILLION AS OF DEC 31, 2017 COMPARED TO $38.3 MILLION AS OF DEC 31, 2016.  Full Article

Cellular Biomedicine Files For Resale Of Up To 2.9 Mln Shares By Selling Stockholders ‍​
Thursday, 1 Mar 2018 06:30am EST 

March 5 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP FILES FOR RESALE OF UP TO 2.9 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING ‍​.  Full Article

Cellular Biomedicine Group Announces $30.6 Mln Investment From Sailing Capital Overseas Investment
Monday, 5 Feb 2018 08:18am EST 

Feb 5 (Reuters) - Cellular Biomedicine Group Inc ::CELLULAR BIOMEDICINE GROUP ANNOUNCES $30.6 MILLION INVESTMENT FROM SAILING CAPITAL OVERSEAS INVESTMENT LTD..CELLULAR BIOMEDICINE GROUP INC - SAILING WILL APPOINT A REPRESENTATIVE TO COMPANY'S BOARD OF DIRECTORS.  Full Article

Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
Thursday, 9 Nov 2017 08:30am EST 

Nov 9 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group reports third quarter financial results and recent operational highlights.Cellular Biomedicine Group Inc- ‍$16.3 million cash and cash equivalents as of September 30, 2017 as compared to $27.3 million as of June 30, 2017​.Cellular Biomedicine Group Inc - Qtrly ‍loss per share $0.43​.Cellular Biomedicine Group Inc - Qtrly net sales and revenue $106,787 versus $10,012‍​.  Full Article

Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
Monday, 6 Nov 2017 07:19am EST 

Nov 6 (Reuters) - Cellular Biomedicine Group Inc :Thermo Fisher Scientific and Cellular Biomedicine Group announce strategic partnership to develop manufacturing processes.Cellular Biomedicine Group Inc - ‍partnership focuses on research and development of an automated cell therapy manufacturing system​.  Full Article

BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin
Tuesday, 19 Sep 2017 06:30am EDT 

Sept 19 (Reuters) - Cellular Biomedicine Group Inc :BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin.  Full Article

Cellular Biomedicine Q2 ‍loss per share $0.43​
Tuesday, 8 Aug 2017 04:31pm EDT 

Aug 8 (Reuters) - Cellular Biomedicine Group Inc ::Cellular Biomedicine Group reports second quarter and first half 2017 financial results and business highlights.Cellular Biomedicine Group Inc - ‍cash and cash equivalents as of June 30, 2017 were $27.3 million compared to $39.3 million as of December 31, 2016​.Cellular Biomedicine Group Inc qtrly ‍loss per share $0.43​.  Full Article

Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
Monday, 15 May 2017 06:23am EDT 

May 15 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group (CBMG) announces the addition of a second clinical site in the expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I clinical trial for its CARD-1 trial in patients with non-hodgkin lymphoma (NHL).Cellular Biomedicine Group Inc - on track to share topline clinical data in Q4 of this year as it becomes available from CARD-1 trial.  Full Article

BRIEF-Cellular Biomedicine Group Qtrly Loss Per Share $0.51

* CELLULAR BIOMEDICINE GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS